Subject to final issuance by the US Patent and Trademark Office, the newly allowed claims will have a July 2016 expiration date.
Gerald Proehl, president and CEO of Santarus, said: “We are pleased to receive this notice of allowance and believe that the allowed patent claims, when issued, will further enhance the intellectual property coverage for our immediate-release Zegerid (omeprazole/sodium bicarbonate) capsules and powder for oral suspension products.”